Hematologic Oncology | Specialty

ASH 2020 Updates in CLL

January 22nd 2021

Forecasting Future Advances Across Oncology

January 21st 2021

Expert discuss their expectations for research and drug development in oncology in the new year.

Parsaclisib Yields Encouraging Clinical Activity in Marginal Zone Lymphoma

January 21st 2021

Tycel Phillips, MD, highlighted the key findings of the phase 2 CITADEL-204 trial.

1-Year DFS Rates Similar Between Ibrutinib and Placebo Following Ibrutinib/Venetoclax in CLL

January 21st 2021

William G. Wierda, MD, PhD, discusses the latest CAPTIVATE findings in patients with chronic lymphocytic leukemia.

Adult Nonmalignant Hematology Is an Endangered Field That Merits Protection

January 21st 2021

The scope of adult nonmalignant hematology can be broad and includes thrombotic and hemorrhagic disorders, transfusion medicine, hemoglobin disorders including sickle cell disease and thalassemia, anemia, thrombocytopenia, leukocytosis, leukopenia, and disorders of iron metabolism.

PANORAMA 3 Study Resets Expectations for Panobinostat in Multiple Myeloma

January 21st 2021

Andrew Spencer, MD, MBBS, FRACP, FRCPA discusses the significance of the PANORAMA 3 study in multiple myeloma.

Treating Young Adult Patients With Philadelphia Chromosome-Negative ALL

January 21st 2021

Prognostic Significance of IDH Mutations in AML

January 21st 2021

FLT3 Testing for Treatment of AML

January 21st 2021

Dr. Hobbs on the Role of Molecular Testing to Determine Resistance in CML

January 19th 2021

Gabriela Hobbs, MD, discusses the role of molecular testing to determine resistance in chronic myeloid leukemia.

Dr. Jabbour on Selecting Ponatinib After Second-Generation TKI Failure in CML

January 19th 2021

Elias Jabbour, MD, discusses selecting ponatinib after failure of a second-generation TKI therapy in chronic myeloid leukemia.

Remaining ECHELON-2 Questions Spark Novel Research Efforts in PTCL

January 19th 2021

Jakub Svoboda, MD, discusses the results of the ECHELON-2 trial and explained where clinical research is headed in peripheral T-cell lymphoma.

FDA Grants Priority Review to Narsoplimab for HSCT-TMA

January 19th 2021

January 19, 2021 — The FDA has granted priority review to the biologics license application for narsoplimab for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy.

Pursuing Pairings of Targeted Agents and HMAs in AML

January 19th 2021

Alison R. Sehgal, MD, discusses some of the novel approaches that have been adopted into practice and ongoing research building on the advances that have been made with targeted therapy.

Frontline Treatment Options in Chronic Lymphocytic Leukemia

January 19th 2021

The experts comment on first-line treatment options in patients with chronic lymphocytic leukemia.

Guidelines for Chronic Lymphocytic Leukemia

January 19th 2021

Dr Brown and Dr Ghia discuss the European Society for Medical Oncology [ESMO] and International Workshop on Chronic Lymphocytic Leukemia [iwCLL] recommended guidelines in assessing and treating chronic lymphocytic leukemia.

Treatment Approaches in Mantle Cell Lymphoma

January 19th 2021

Accurately Diagnosing Mantle Cell Lymphoma

January 19th 2021

Capitalizing on Cellular Therapies in Lymphoma and Myeloma

January 18th 2021

In our exclusive interview, Dr. Kansagra, Dr. D’Souza, and Dr. Dholaria provided an in-depth look into the current state of cellular therapy in hematologic malignancies, the benefits and drawbacks of approved and investigational products, and new constructs for CAR T in multiple myeloma and lymphoma.

Could Orca-T Unlock New Path of Reduced Mortality, Prevent GVHD Posttransplant?

January 18th 2021

Steven Devine, MD, discusses the non-relapse mortality data with Orca-T and how this technologic approach is changing how providers approach patients with hematologic malignancies following transplant.